Overview
- A large study published in The Lancet found that people diagnosed with polyendocrine metabolic ovarian syndrome (PMOS) face much higher cardiovascular risks, including about 4.4 times the risk of arterial heart disease and 3.5 times the risk of heart attack or stroke.
- The analysis used health records for more than 2.4 million women aged 18 to 50 collected from 2000 to 2022 and included over 413,000 with a PMOS diagnosis.
- Experts say the findings bolster the 2026 renaming from PCOS to PMOS by highlighting the condition's broad endocrine and metabolic effects beyond the ovaries.
- Patient accounts and firms such as Daye describe frequent dismissal in primary care and say private or at‑home hormone testing has helped some people get a diagnosis after long delays.
- PMOS is thought to affect roughly 10–13% of women of reproductive age and may be underdiagnosed, so clinicians and patients should expect more emphasis on screening for blood pressure, lipids and glucose and on managing modifiable risks such as obesity and smoking.